Mobile

An open-label, randomized phase II study of the efficacy and safety of indisulam (E7070) in combination with capecitabine versus capecitabine monotherapy for the treatment of metastatic breast cancer...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000774-31

An open-label, randomized phase II study of the efficacy and safety of indisulam (E7070) in combination with capecitabine versus capecitabine monotherapy for the treatment of metastatic breast cancer patients following prior anthracycline and taxane therapy

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the efficacy, safety and tolerability of indisulam (I) in combination with capecitabine (C) versus capecitabine (C) monotherapy in patients with metastatic breast cancer following prior anthracycline and taxane therapy. The primary objective is to demonstrate superior time to progression with the IC combination regimen.

Critère d'inclusion

  • Treatment of metastatic breast cancer

Liens